单位：[1]Department of Ophthalmology, Shandong Provincial Hospital affiliated to Shandong University, Jinan, China[2]Department of School of public health, Taishan Medical University, Taian, China[3]Department of Ophthalmology, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China临床科室眼科眼科首都医科大学附属北京友谊医院[4]Department of Pediatrics, Shandong Provincial Hospital affiliated to Shandong University, Jinan, China
Purpose: To evaluate the therapeutic efficacy of conbercept for the treatment of diabetic macular edema (DME) with different baseline visual acuity. Methods: This is a retrospective, comparative study. A total of 107 eyes of 107 patients were included. According to the levels of baseline best corrected visual acuity (BCVA) and therapeutic regimen, the DME patients were divided into four groups: conbercept treatment subgroup with worse baseline VA (less than 69 letters, Snellen equivalent, 20/50 or worse; n = 37), untreated subgroup with worse baseline VA(n = 28); conbercept treatment subgroup with better baseline VA (78 to 69 letters, Snellen equivalent, 20/32 to 20/40; n = 25), untreated subgroup (n = 17). Patients received one initial intravitreal injection followed by re-treatments based on BCVA loss or increase of central macular thickness (CMT). Results: At month 12, the mean improvement of BCVA was significantly higher in both worse baseline VA group and better baseline VA group with conbercept treatment than that of corresponding untreated controls:18(15) letters vs. -4(6) letters, P < 0.001; 7(1) letters vs. -5(5) letters; P < 0.001; respectively. At month12 the mean CMT from baseline was significantly declined in both worse baseline VA group and better baseline VA group with conbercept treatment than that of respective untreated controls (-212.8 +/- 11.9 vs.-44.3 +/- 35.3 mu m,P < 0.001; -116.1 +/- 88.9vs.-33.7 +/- 49.8 mu m, P = 0.001; respectively). At the end of twelve month follow-up, the BCVA improvement and CMT declination in worse baseline VA group were more prominent than that in better baseline group (P < 0.001). The mean numbers of injections were 6.7 +/- 0.9, 6.5 +/- 1.1 in worse baseline VA group and better baseline VA group, respectively (P = 0.35). The two groups have no significant difference in the number of injections. Conclusion: Conbercept was effective in the treatment of DME at different levels of baseline BCVA. For worse baseline VA, BCVA improvement was more prominent than that of better VA subgroup.
基金：
Shandong Nature Science Foundation [ZR2015HM026, ZR2017MH021]
第一作者单位：[1]Department of Ophthalmology, Shandong Provincial Hospital affiliated to Shandong University, Jinan, China
通讯作者：
通讯机构：[1]Department of Ophthalmology, Shandong Provincial Hospital affiliated to Shandong University, Jinan, China[4]Department of Pediatrics, Shandong Provincial Hospital affiliated to Shandong University, Jinan, China[*1]Department of Ophthalmology, Shandong Provincial Hospital affiliated to Shandong University, 324 Jingwu Road, Jinan, China 250021[*2]Department of Pediatrics, Shandong Provincial Hospital affiliated to Shandong University, 324 Jingwu Road, Jinan, China. 250021
推荐引用方式(GB/T 7714)：
Li Fengjiao,Zhang Le,Wang Yanling,et al.One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema[J].CURRENT EYE RESEARCH.2018,43(2):218-223.doi:10.1080/02713683.2017.1379542.
APA：
Li, Fengjiao,Zhang, Le,Wang, Yanling,Xu, Wenwen,Jiao, Wanzhen...&Zhao, Bojun.(2018).One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema.CURRENT EYE RESEARCH,43,(2)
MLA：
Li, Fengjiao,et al."One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema".CURRENT EYE RESEARCH 43..2(2018):218-223
